Cancel fossil fuel extraction contracts to combat climate change
Peer-Reviewed Publication
Updates every hour. Last Updated: 26-Dec-2025 21:11 ET (27-Dec-2025 02:11 GMT/UTC)
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for approximately 30% of global mortality and imposing a substantial economic burden on society. Due to the high heterogeneity of CVD, which involves diverse pathological mechanisms and clinical phenotypes, existing diagnostic tools such as cardiac magnetic resonance imaging and tissue biopsies face limitations including technical constraints, invasiveness, and high costs. Consequently, there is an urgent need to develop simple, cost-effective, and efficient methods for early screening and risk assessment.
Cervical cancer is the second most prevalent malignancy in female reproductive system and a major cause of morbidity and mortality worldwide. Its proliferation and migration are closely associated with cellular zinc (Zn2+), which is meticulously regulated by the human Zn2+ importers (Zrt-/Irt-like proteins, hZIPs) and exporters (zinc transporter, hZnTs).
Varicella-zoster virus (VZV) is a highly contagious human herpesvirus responsible for chickenpox upon primary infection and shingles upon viral reactivation. While Varicella-zoster immune globulin (VZIG) can offer post-exposure protection for high-risk individuals, structural insights into neutralizing antibodies (nAbs) derived from natural infection remain limited. Glycoprotein E (gE), the most abundant and immunogenic envelope protein of VZV, plays an essential role in viral infection and is the sole antigen in the recombinant zoster vaccine.
Cervical cancer will be the first human cancer eliminated through coordinated global action. A new special issue of Cancer Biology & Medicine brings together leading experts from around the world to examine progress, challenges, and innovations in prevention, screening, and treatment.
This study presents a comprehensive benchmarking of human-derived transcription activation domains (hTADs) for use in CRISPR-based artificial transcription factors (ATFs), aiming to circumvent the immunogenicity associated with viral TADs like VP64 and VPR. The authors systematically compared eight hTADs—CITED1, CITED2, MYB, KLF7, CSRNP1, NFZ, MSN, and p65HSF1—fused to dCas9. While several hTADs surpassed VP64 in activating a synthetic EGFP reporter, none outperformed VPR at endogenous gene targets.